Why Did SoundHound AI Stock Go Up?
SoundHound AI (NASDAQ:SOUN) has moved higher in recent days, breaking…
Sell
50
ESPR Quote, Financials, Valuation and Earnings
Last price:
$3.11
Seasonality move
:
17.38%
Day range:
$2.97 - $3.21
52-week range:
$0.69 - $4.18
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.06x
P/B ratio:
--
Volume:
7.1M
Avg. volume:
5.6M
1-year change:
44.09%
Market cap:
$751.5M
Revenue:
$332.3M
EPS (TTM):
-$0.54
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ESPR
Esperion Therapeutics, Inc.
|
$160.1M | $0.27 | 68.53% | -98.39% | $6.50 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.37 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ESPR
Esperion Therapeutics, Inc.
|
$3.17 | $6.50 | $751.5M | -- | $0.00 | 0% | 2.06x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$5.48 | $0.85 | $691.4M | 9.21x | $0.80 | 0% | 10.65x |
|
NNVC
NanoViricides, Inc.
|
$1.15 | $6.50 | $20.7M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.93 | $2.00 | $763.2K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.21 | $7.00 | $7M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ESPR
Esperion Therapeutics, Inc.
|
408.15% | 2.160 | 109.82% | 0.65x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -3.190 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.780 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | 0.905 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -2.522 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ESPR
Esperion Therapeutics, Inc.
|
$46M | -$10M | -60.77% | -- | -11.41% | -$23.9M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Esperion Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns ESPR or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -35.89% compared to Esperion Therapeutics, Inc.'s net margin of -255.85%. Esperion Therapeutics, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital ESPREsperion Therapeutics, Inc.52.71% -$0.16 $146.5M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About ESPR or NBY?
Esperion Therapeutics, Inc. has a consensus price target of $6.50, signalling upside risk potential of 105.09%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -84.49%. Given that Esperion Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Esperion Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ESPREsperion Therapeutics, Inc.3 1 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is ESPR or NBY More Risky?
Esperion Therapeutics, Inc. has a beta of 1.043, which suggesting that the stock is 4.293% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.
-
Which is a Better Dividend Stock ESPR or NBY?
Esperion Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Esperion Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ESPR or NBY?
Esperion Therapeutics, Inc. quarterly revenues are $87.3M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Esperion Therapeutics, Inc.'s net income of -$31.3M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Esperion Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 9.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics, Inc. is 2.06x versus 10.65x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESPREsperion Therapeutics, Inc.2.06x -- $87.3M -$31.3M NBYNovaBay Pharmaceuticals, Inc.10.65x 9.21x $521K -$1.3M
-
Which has Higher Returns ESPR or NNVC?
NanoViricides, Inc. has a net margin of -35.89% compared to Esperion Therapeutics, Inc.'s net margin of --. Esperion Therapeutics, Inc.'s return on equity of -- beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital ESPREsperion Therapeutics, Inc.52.71% -$0.16 $146.5M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About ESPR or NNVC?
Esperion Therapeutics, Inc. has a consensus price target of $6.50, signalling upside risk potential of 105.09%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 465.22%. Given that NanoViricides, Inc. has higher upside potential than Esperion Therapeutics, Inc., analysts believe NanoViricides, Inc. is more attractive than Esperion Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ESPREsperion Therapeutics, Inc.3 1 0 NNVCNanoViricides, Inc.1 0 0 -
Is ESPR or NNVC More Risky?
Esperion Therapeutics, Inc. has a beta of 1.043, which suggesting that the stock is 4.293% more volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.439%.
-
Which is a Better Dividend Stock ESPR or NNVC?
Esperion Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ESPR or NNVC?
Esperion Therapeutics, Inc. quarterly revenues are $87.3M, which are larger than NanoViricides, Inc. quarterly revenues of --. Esperion Therapeutics, Inc.'s net income of -$31.3M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Esperion Therapeutics, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics, Inc. is 2.06x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESPREsperion Therapeutics, Inc.2.06x -- $87.3M -$31.3M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns ESPR or OGEN?
Oragenics, Inc. has a net margin of -35.89% compared to Esperion Therapeutics, Inc.'s net margin of --. Esperion Therapeutics, Inc.'s return on equity of -- beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital ESPREsperion Therapeutics, Inc.52.71% -$0.16 $146.5M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About ESPR or OGEN?
Esperion Therapeutics, Inc. has a consensus price target of $6.50, signalling upside risk potential of 105.09%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 115.66%. Given that Oragenics, Inc. has higher upside potential than Esperion Therapeutics, Inc., analysts believe Oragenics, Inc. is more attractive than Esperion Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ESPREsperion Therapeutics, Inc.3 1 0 OGENOragenics, Inc.1 0 0 -
Is ESPR or OGEN More Risky?
Esperion Therapeutics, Inc. has a beta of 1.043, which suggesting that the stock is 4.293% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.685%.
-
Which is a Better Dividend Stock ESPR or OGEN?
Esperion Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ESPR or OGEN?
Esperion Therapeutics, Inc. quarterly revenues are $87.3M, which are larger than Oragenics, Inc. quarterly revenues of --. Esperion Therapeutics, Inc.'s net income of -$31.3M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Esperion Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics, Inc. is 2.06x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESPREsperion Therapeutics, Inc.2.06x -- $87.3M -$31.3M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns ESPR or PTN?
Palatin Technologies has a net margin of -35.89% compared to Esperion Therapeutics, Inc.'s net margin of --. Esperion Therapeutics, Inc.'s return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ESPREsperion Therapeutics, Inc.52.71% -$0.16 $146.5M PTNPalatin Technologies-- -- -- -
What do Analysts Say About ESPR or PTN?
Esperion Therapeutics, Inc. has a consensus price target of $6.50, signalling upside risk potential of 105.09%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Esperion Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Esperion Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ESPREsperion Therapeutics, Inc.3 1 0 PTNPalatin Technologies0 0 0 -
Is ESPR or PTN More Risky?
Esperion Therapeutics, Inc. has a beta of 1.043, which suggesting that the stock is 4.293% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock ESPR or PTN?
Esperion Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ESPR or PTN?
Esperion Therapeutics, Inc. quarterly revenues are $87.3M, which are larger than Palatin Technologies quarterly revenues of --. Esperion Therapeutics, Inc.'s net income of -$31.3M is higher than Palatin Technologies's net income of --. Notably, Esperion Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics, Inc. is 2.06x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESPREsperion Therapeutics, Inc.2.06x -- $87.3M -$31.3M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns ESPR or TOVX?
Theriva Biologics, Inc. has a net margin of -35.89% compared to Esperion Therapeutics, Inc.'s net margin of --. Esperion Therapeutics, Inc.'s return on equity of -- beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital ESPREsperion Therapeutics, Inc.52.71% -$0.16 $146.5M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About ESPR or TOVX?
Esperion Therapeutics, Inc. has a consensus price target of $6.50, signalling upside risk potential of 105.09%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3283.28%. Given that Theriva Biologics, Inc. has higher upside potential than Esperion Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Esperion Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ESPREsperion Therapeutics, Inc.3 1 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is ESPR or TOVX More Risky?
Esperion Therapeutics, Inc. has a beta of 1.043, which suggesting that the stock is 4.293% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.729%.
-
Which is a Better Dividend Stock ESPR or TOVX?
Esperion Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Esperion Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ESPR or TOVX?
Esperion Therapeutics, Inc. quarterly revenues are $87.3M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Esperion Therapeutics, Inc.'s net income of -$31.3M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Esperion Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Esperion Therapeutics, Inc. is 2.06x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ESPREsperion Therapeutics, Inc.2.06x -- $87.3M -$31.3M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Goldman Sachs Going to Go Up?
Shares of financial giant Goldman Sachs (NYSE:GS) have soared by…
How High Will MSTR Stock Go?
After several months of pressure, shares of Bitcoin treasury Strategy…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
69
INTC alert for Jan 23
Intel Corp. [INTC] is down 17.6% over the past day.
Buy
51
APGE alert for Jan 23
Apogee Therapeutics, Inc. [APGE] is down 10.71% over the past day.
Buy
70
BNR alert for Jan 23
Burning Rock Biotech Ltd. [BNR] is down 12.45% over the past day.
